Lercanidipine Zentiva (Lercanidipine Hydrochloride)

The drug blocks L‑type calcium channels in arterial smooth muscle, preventing calcium entry that would otherwise cause contraction. This selective inhibition leads to vasodilation, decreasing peripheral resistance and consequently lowering systemic blood pressure.

The exact dose is determined by the prescribing clinician based on the patient’s condition, response, and any co‑existing medical issues. Dosage adjustments are made individually and should follow the healthcare professional’s guidance.

Safety data for Lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine class of calcium channel blockers, offering once‑daily dosing and a favorable side‑effect profile compared with some older agents. It is often considered when patients need effective blood‑pressure control with minimal impact on heart rate.

Store the tablets at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep out of reach of children and do not use after the expiry date printed on the packaging.

Lercanidipine Zentiva is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew it.

Serious adverse events, although rare, include angioedema, severe hypotension, myocardial infarction, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden faintness, chest pain, or unusual fatigue.

Individuals with known hypersensitivity to lercanidipine or any component of the formulation should avoid the drug. Caution is also advised for patients with severe hepatic impairment, uncontrolled heart failure, or those taking contraindicated medications such as strong CYP3A4 inhibitors.